Replimune Group Inc Revenue Growth Rates (REPL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Replimune Group Inc   (NASDAQ: REPL)
 

REPL's Revenue Growth by Quarter and Year

Replimune Group Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/REPL/growth
https://api.csimarket.com/api/v1/companies/REPL/fundamentals
https://api.csimarket.com/api/v1/companies/REPL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
REPL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 0.00
1st Quarter June 0.00
FY 0.00





REPL Revenue second quarter 2026 Y/Y Growth Comment
Replimune Group Inc in the second quarter 2026 recorded of $ 0.00 millions.

According to the results reported in the second quarter 2026, Replimune Group Inc achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Replimune Group Inc ' s Revenue no change of 0% ranks overall at the positon no. in the second quarter 2026.


REPL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June -
FY   -

Financial Statements
Replimune Group Inc 's second quarter 2026 Revenue $ 0.00 millions REPL's Income Statement
Replimune Group Inc 's second quarter 2025 Revenue $ 0.00 millions Quarterly REPL's Income Statement


REPL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September -
1st Quarter June -
FY (Year on Year)   -


Back to REPL Growth rate Comparisons >> Back to REPL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Replimune Group Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


REPL's II. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


REPL's II. Quarter Q/Q Revenue Comment


Replimune Group Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Sep 30 2026 period, Replimune Group Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Replimune Group Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2026 period, Replimune Group Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Replimune Group Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
REPL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Novavax inc -3.05%$ -3.048 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Zai Lab Limited-6.79%$ -6.794 millions
Solventum Corporation-7.01%$ -7.013 millions
Janux Therapeutics Inc -7.11%$ -7.110 millions
Accuray Incorporated-7.51%$ -7.510 millions
Dentsply Sirona Inc -7.52%$ -7.522 millions
Inspire Medical Systems inc -7.61%$ -7.613 millions
Airsculpt Technologies Inc -8.71%$ -8.713 millions
Nature s Sunshine Products inc -8.94%$ -8.939 millions
Adapthealth Corp -9.10%$ -9.102 millions


About Replimune Group Inc Revenue Growth Rates (REPL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Replimune Group Inc (CIK 1737953).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-067722
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Replimune Group Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.